Solara Active Pharma Sciences Limited (BOM:890202)
India · Delayed Price · Currency is INR 308.70
+35.20 (12.87%)
At close: Apr 1, 2026
BOM:890202 Revenue
In the fiscal year ending March 31, 2026, Solara Active Pharma Sciences had annual revenue of 13.75B INR with 7.12% growth. Solara Active Pharma Sciences had revenue of 3.92B in the quarter ending March 31, 2026, with 43.58% growth.
Revenue
13.75B
Revenue Growth
+7.12%
P/S Ratio
2.03
Revenue / Employee
7.75M
Employees
1,775
Market Cap
27.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 13.75B | 913.80M | 7.12% |
| Mar 31, 2025 | 12.84B | -51.60M | -0.40% |
| Mar 31, 2024 | 12.89B | -1.55B | -10.73% |
| Mar 31, 2023 | 14.44B | 1.75B | 13.83% |
| Mar 31, 2022 | 12.68B | -3.49B | -21.56% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 22.27B |
| Shilpa Medicare | 14.33B |
| Bajaj HealthCare | 6.11B |
| NGL Fine-Chem | 4.47B |
| Aarey Drugs & Pharmaceuticals | 3.91B |
| Anlon Healthcare | 1.70B |
| Gujarat Themis Biosyn | 1.59B |
| Influx Healthtech | 1.24B |
Solara Active Pharma Sciences News
- 2 days ago - Solara Active Pharma Sciences Ltd (BOM:541540) Q4 2026 Earnings Call Highlights: Record Revenue ... - GuruFocus
- 19 days ago - Solara Active Pharma share price jumps over 4% after USFDA closes Puducherry facility inspection with VAI status - Business Upturn
- 3 months ago - Solara Active Pharma Sciences Ltd (BOM:541540) Q3 2026 Earnings Call Highlights: Strategic ... - GuruFocus
- 3 months ago - Q3 2026 Solara Active Pharma Sciences Ltd Earnings Call Transcript - GuruFocus
- 6 months ago - Solara Active Pharma’s Mangalore facility clears US FDA inspection with VAI classification - Business Upturn
- 6 months ago - Solara Active Pharma Sciences Ltd (BOM:541540) Q2 2026 Earnings Call Highlights: Navigating ... - GuruFocus
- 6 months ago - Q2 2026 Solara Active Pharma Sciences Ltd Earnings Call Transcript - GuruFocus
- 6 months ago - Solara Active Pharma shares slump nearly 9% today after reporting Q2 net loss - Business Upturn